172 related articles for article (PubMed ID: 10639386)
1. In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori.
Kawakami Y; Akahane T; Yamaguchi M; Oana K; Takahashi Y; Okimura Y; Okabe T; Gotoh A; Katsuyama T
Antimicrob Agents Chemother; 2000 Feb; 44(2):458-61. PubMed ID: 10639386
[TBL] [Abstract][Full Text] [Related]
2. A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the motility of Helicobacter pylori.
Tsutsui N; Taneike I; Ohara T; Goshi S; Kojio S; Iwakura N; Matsumaru H; Wakisaka-Saito N; Zhang HM; Yamamoto T
Antimicrob Agents Chemother; 2000 Nov; 44(11):3069-73. PubMed ID: 11036024
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory action of a novel proton pump inhibitor, rabeprazole, and its thioether derivative against the growth and motility of clarithromycin-resistant Helicobacter pylori.
Ohara T; Goshi S; Taneike I; Tamura Y; Zhang HM; Yamamoto T
Helicobacter; 2001 Jun; 6(2):125-9. PubMed ID: 11422467
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole.
Miwa H; Yamada T; Sato K; Ohta K; Ohkura R; Murai T; Nagahara A; Takei Y; Ogihara T; Sato N
Dig Dis Sci; 2000 Jan; 45(1):77-82. PubMed ID: 10695617
[TBL] [Abstract][Full Text] [Related]
5. [In vitro susceptibilities of Helicobacter pylori strains from children to proton pump inhibitors and its thioether derivative].
Taneike I; Tamura Y; Shimizu T; Yamashiro Y; Toyoda S; Yamamoto T
Kansenshogaku Zasshi; 2000 Jul; 74(7):601-2. PubMed ID: 10965666
[No Abstract] [Full Text] [Related]
6. Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication.
Sharara AI
Expert Rev Anti Infect Ther; 2005 Dec; 3(6):863-70. PubMed ID: 16307499
[TBL] [Abstract][Full Text] [Related]
7. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole.
Miwa H; Ohkura R; Murai T; Sato K; Nagahara A; Hirai S; Watanabe S; Sato N
Aliment Pharmacol Ther; 1999 Jun; 13(6):741-6. PubMed ID: 10383502
[TBL] [Abstract][Full Text] [Related]
8. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
Inaba T; Mizuno M; Kawai K; Yokota K; Oguma K; Miyoshi M; Take S; Okada H; Tsuji T
J Gastroenterol Hepatol; 2002 Jul; 17(7):748-53. PubMed ID: 12121503
[TBL] [Abstract][Full Text] [Related]
9. Review article: the pharmacology of rabeprazole.
Williams MP; Pounder RE
Aliment Pharmacol Ther; 1999 Aug; 13 Suppl 3():3-10. PubMed ID: 10491723
[TBL] [Abstract][Full Text] [Related]
10. Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor.
Tsuchiya M; Imamura L; Park JB; Kobashi K
Biol Pharm Bull; 1995 Aug; 18(8):1053-6. PubMed ID: 8535394
[TBL] [Abstract][Full Text] [Related]
11. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin.
Kawabata H; Habu Y; Tomioka H; Kutsumi H; Kobayashi M; Oyasu K; Hayakumo T; Mizuno S; Kiyota K; Nakajima M; Kimoto K; Inokuchi H; Kawai K
Aliment Pharmacol Ther; 2003 Jan; 17(2):259-64. PubMed ID: 12534411
[TBL] [Abstract][Full Text] [Related]
12. Antibacterial properties of lansoprazole alone and in combination with antimicrobial agents against Helicobacter pylori.
Nakao M; Tada M; Tsuchimori K; Uekata M
Eur J Clin Microbiol Infect Dis; 1995 May; 14(5):391-9. PubMed ID: 7556227
[TBL] [Abstract][Full Text] [Related]
13. Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
Miki I; Aoyama N; Sakai T; Shirasaka D; Wambura CM; Maekawa S; Kuroda K; Tamura T; Kita T; Sakaeda T; Okumura K; Kasuga M
Eur J Gastroenterol Hepatol; 2003 Jan; 15(1):27-33. PubMed ID: 12544691
[TBL] [Abstract][Full Text] [Related]
14. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.
Vallve M; Vergara M; Gisbert JP; Calvet X
Aliment Pharmacol Ther; 2002 Jun; 16(6):1149-56. PubMed ID: 12030958
[TBL] [Abstract][Full Text] [Related]
15. Review article: rabeprazole-based therapy in Helicobacter pylori eradication.
Barth J; Hahne W
Aliment Pharmacol Ther; 2002 Mar; 16 Suppl 1():31-3. PubMed ID: 11849125
[TBL] [Abstract][Full Text] [Related]
16. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.
Furuta T; Shirai N; Xiao F; Takashita M; Sugimoto M; Kajimura M; Ohashi K; Ishizaki T
Hepatogastroenterology; 2003; 50(54):2274-8. PubMed ID: 14696516
[TBL] [Abstract][Full Text] [Related]
17. [Comparative study of proton pump inhibitors].
Herszényi L; Tulassay Z
Orv Hetil; 2001 Sep; 142(36):1953-61. PubMed ID: 11680100
[TBL] [Abstract][Full Text] [Related]
18. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori.
Iwahi T; Satoh H; Nakao M; Iwasaki T; Yamazaki T; Kubo K; Tamura T; Imada A
Antimicrob Agents Chemother; 1991 Mar; 35(3):490-6. PubMed ID: 2039199
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of lansoprazole in eradication of Helicobacter pylori.
Takimoto T; Ido K; Taniguchi Y; Satoh K; Saifuku K; Kihira K; Yoshida Y; Kimura K
J Clin Gastroenterol; 1995; 20 Suppl 2():S121-4. PubMed ID: 7594327
[TBL] [Abstract][Full Text] [Related]
20. Retreatment of H. pylori with dual therapy using high doses of rabeprazole or lansoprazole can be effective.
Furuta T; Shirai N; Sugimoto M; Ohashi K; Ishizaki T
Aliment Pharmacol Ther; 2003 Dec; 18(11-12):1175-6. PubMed ID: 14653841
[No Abstract] [Full Text] [Related]
[Next] [New Search]
